Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations

被引:48
|
作者
Cevik, Dilek [1 ,2 ]
Yildiz, Gokhan [1 ,2 ]
Ozturk, Mehmet [1 ,2 ,3 ]
机构
[1] Bilkent Univ, Dept Mol Biol & Genet, BilGen Genet & Biotechnol Ctr, TR-06800 Ankara, Turkey
[2] Univ Grenoble 1, INSERM, Ctr Rech, U823, F-38706 La Tronche, France
[3] Dokuz Eylul Univ, Adv Biomed Res Ctr, TR-35340 Izmir, Turkey
关键词
Hepatocellular carcinoma; Liver cancer; Telomerase reverse transcriptase; Promoter mutation; Cellular immortality; Telomerase reverse transcriptase gene; HIGH-FREQUENCY; LIVER CANCERS; CELLS; MECHANISMS;
D O I
10.3748/wjg.v21.i1.311
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To determine the mutation status of human telomerase reverse transcriptase gene (TERT) promoter region in hepatocellular carcinoma (HCC) from different geographical regions. METHODS: We analyzed the genomic DNA sequences of 59 HCC samples comprising 15 cell lines and 44 primary tumors, collected from patients living in Asia, Europe and Africa. We amplified a 474 bp DNA fragment of the promoter region of TERT gene including the 1295228 and 1295250 sequence of chromosome 5 by using PCR. Amplicons were then sequenced by Sanger technique and the sequence data were analyzed with by using DNADynamo software in comparison with wild type TERT gene sequence as a reference. RESULTS: The TERT mutations were found highly frequent in HCC. Eight of the fifteen tested cell lines displayed C228T mutation, and one had C250T mutation with a mutation frequency up to 60%. All of the mutations were heterozygous and mutually exclusive. Ten out of forty-four tumors displayed C228T mutation, and additional five tumors had C250T mutation providing evidence for mutation frequency of 34% in primary tumors. Considering the geographic origins of HCC tumors tested, TERT promoter mutation frequencies were higher in African (53%), when compared to non-African (24%) tumors (P = 0.056). There was also a weak inverse correlation between TERT promoter mutations and murine double minute 2 single nucleotide polymorphism 309 TG polymorphism (P = 0.058). Mutation frequency was nearly two times higher in established HCC cell. CONCLUSION: TERT promoter is one of most frequent mutational targets in liver cancer, and hepatocellular carcinogenesis is highly associated with the loss of telomere-dependent cellular senescence control.
引用
收藏
页码:311 / 317
页数:7
相关论文
共 50 条
  • [21] Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas
    Xing Fan
    Yinyan Wang
    Yong Liu
    Xing Liu
    Chuanbao Zhang
    Lei Wang
    Shaowu Li
    Jun Ma
    Tao Jiang
    Journal of Neuro-Oncology, 2016, 128 : 455 - 462
  • [22] Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas
    Fan, Xing
    Wang, Yinyan
    Liu, Yong
    Liu, Xing
    Zhang, Chuanbao
    Wang, Lei
    Li, Shaowu
    Ma, Jun
    Jiang, Tao
    JOURNAL OF NEURO-ONCOLOGY, 2016, 128 (03) : 455 - 462
  • [23] Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates
    Balakumar, Shailaja
    Pai, Rekha
    Chacko, Ari G.
    Patel, Bimal
    Nancy, Rachel
    Balakrishnan, Rajesh
    Sarkar, Sauradeep
    Sampath, Gowri
    Chacko, Geeta
    NEUROLOGY INDIA, 2022, 70 (03) : 953 - 959
  • [24] Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations
    Tornesello, Maria Lina
    Cerasuolo, Andrea
    Starita, Noemy
    Amiranda, Sara
    Bonelli, Patrizia
    Tuccillo, Franca Maria
    Buonaguro, Franco M.
    Buonaguro, Luigi
    Tornesello, Anna Lucia
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [25] Patterns of Telomerase reverse transcriptase (TERT) promoter mutations in melanoma and bladder cancer
    Kumar, Rajiv
    Heidenreich, Barbara
    Hosen, Ismail
    Rachakonda, Sivaramakrishna
    Hemminki, Kari
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Correction: Corrigendum: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions
    Jean Charles Nault
    Maxime Mallet
    Camilla Pilati
    Julien Calderaro
    Paulette Bioulac-Sage
    Christophe Laurent
    Alexis Laurent
    Daniel Cherqui
    Charles Balabaud
    Jessica Zucman-Rossi
    Nature Communications, 4
  • [27] High frequency of telomerase reverse transcriptase (tert) promoter somatic mutations in hepatocellular carcinoma and pre-neoplastic lesions
    Nault, Jean-Charles
    Mallet, Maxime
    Pilati, Camilla
    Calderaro, Julien
    Bioulac-Sage, Paulette
    Laurent, Christophe
    Laurent, Alexis
    Cherqui, Daniel
    Balabaud, Charles
    Zucman-Rossi, Jessica
    HEPATOLOGY, 2013, 58 : 1057A - 1057A
  • [28] Telomerase reverse transcriptase (TERT) promoter mutation correlated with intratumoral heterogeneity in hepatocellular carcinoma
    Kwa, Wit Thun
    Effendi, Kathryn
    Yamazaki, Ken
    Kubota, Naoto
    Hatano, Mami
    Ueno, Akihisa
    Masugi, Yohei
    Sakamoto, Michiie
    PATHOLOGY INTERNATIONAL, 2020, 70 (09) : 624 - 632
  • [29] Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma
    Ako, Soichiro
    Nouso, Kazuhiro
    Kinugasa, Hideaki
    Matsushita, Hiroshi
    Terasawa, Hiroyuki
    Adachi, Takuya
    Wada, Nozomu
    Takeuchi, Yasuto
    Mandai, Mari
    Onishi, Hideki
    Ikeda, Fusao
    Shiraha, Hidenori
    Takaki, Akinobu
    Fujioka, Shinichi
    Mimura, Tetsushige
    Okada, Hiroyuki
    ONCOLOGY, 2020, 98 (05) : 311 - 317
  • [30] Telomerase Reverse Transcriptase Promoter Methylation Is Related to a Risk of Recurrence in Hepatocellular Carcinoma Reply
    Nault, Jean-Charles
    Calderaro, Julien
    Zucman-Rossi, Jessica
    HEPATOLOGY, 2016, 63 (01) : 342 - 342